# FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

> **NCT03042780** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 2 (actual)

## Conditions studied

- Gastro-enteropancreatic Neuroendocrine Tumor
- Pancreatic Cancer
- Neuroendocrine Carcinomas of Pancreas
- Islet Cell Carcinoma

## Interventions

- **DRUG:** FOLFIRINOX
- **DRUG:** Granulocyte colony-stimulating factor (G-CSF)

## Key facts

- **NCT ID:** NCT03042780
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-01
- **Primary completion:** 2018-01-03
- **Final completion:** 2018-09-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2020-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03042780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03042780, "FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03042780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*